On April 19, 2025, the " Lexpress Legal Service Innovation and Development Forum and the 2025 Spring Release of the Lexpress Guide" was successfully held in Beijing. Over 200 participants, including experts, scholars, entrepreneurs, law firm managers, corporate legal professionals, legal technology experts, and senior lawyers and leaders in fields such as construction engineering, wealth management, industrial investment funds, biopharmaceuticals and healthcare, and capital markets, gathered to discuss hot topics in professional development and innovation, fostering exchanges and cooperation within the industry.

The forum prominently released the "Lexpress Guide," focusing on five major fields: construction engineering, wealth management, industrial investment funds, biopharmaceuticals and healthcare, and capital markets. It also introduced the "Series of Research Reports on Legal Services (2024)," analyzing lawyer and law firm brands through multiple dimensions to generate the "Brand Star" honors for lawyers and "Brand Influence" awards for law firms.

With outstanding strength and a strong industry reputation in the biopharmaceutical and medical fields, as well as the industrial investment fund sector, Llinks lawyer was successfully included in the Legal News "Premium Legal Service Brand Guide (2024): Biopharmaceuticals and Medical Field" and the "Premium Legal Service Brand Guide (2024): Industrial Investment Fund Field." Llinks partner Mr. Yiguang Lu and contractual partner Ms. Aurora Zhang were respectively recognized as "Leading Lawyer" in the biopharmaceutical and medical field and "Highly Regarded Lawyer" in the industrial investment fund field.

Leading Lawyer

Yiguang Lu

Mr. Yiguang Lu has long been dedicated to compliance and dispute resolution in the fields of healthcare, pharmaceuticals, and medical insurance. His expertise includes the legality assessment of major decisions and crisis management for medical institutions and pharmaceutical enterprises; compliance matters for pharmaceutical products before and after market approval; and the compliant use of medical insurance funds by designated pharmaceutical companies. He serves as legal counsel for numerous medical institutions, pharmaceutical companies, as well as health and drug regulatory authorities.

Mr. Lu has a profound understanding of the healthcare industry. Firstly, he has conducted in-depth research on defining whether an activity constitutes medical practice (unlicensed practice) and has handled multiple administrative penalty cases related to unlicensed practice. Secondly, he provides legal opinions regarding whether medical institutions are involved in renting or contracting out departments, practicing beyond their authorized scope, or employing non-healthcare personnel, and he has extensive experience in managing complex medical disputes. Thirdly, Mr. Lu has conducted in-depth research on compliance in international medical tourism, offering professional legal advice on how to conduct cross-border medical services and the use of drugs and medical devices across borders.

Mr. Lu has long provided compliance opinions on the research and registration of pharmaceutical products prior to market entry, particularly in areas such as clinical research compliance, key points of ethical review, management of compassionate use of drugs and medical devices, design of informed consent clauses, and resolution of clinical research disputes.

He also possesses rich experience in ensuring compliance in the production, distribution, promotion, and use of pharmaceutical products post-market, including responsibilities of Marketing Authorization Holders (MAH), advertising review, cross-border circulation of drugs and medical devices, off-label use, and handling adverse events.

Additionally, he has conducted in-depth research on defining drugs (including counterfeit and substandard drugs) and medical devices. Mr. Lu has specialized research on the compliance, promotion, and use of health foods, special medical purpose foods, disinfection products, and cosmetics, which are related to life and health. He has systematically researched legal risk management for pharmaceutical companies expanding overseas, including contract risk prevention, overseas cooperation pathways, and regulatory differences in various regions.

Mr. Lu has handled numerous cases involving the use of medical insurance funds, assisting companies in resolving administrative disputes with medical insurance departments, representing them in hearings, administrative reviews, and administrative litigation, and managing cases that intersect with criminal law to protect the legal rights of defendants. He also provides specialized legal services and training for pharmaceutical companies to ensure compliant use of medical insurance funds.

Mr. Lu has authored several books, including but not limited to "Practical Legal Risk Management for Medical Institutions and Pharmaceutical Companies," "Analysis of Typical Cases in Medical Compliance," and "Legal Practice and Typical Cases in Medical Aesthetics."

In 2011, Mr. Lu was honored as an "Outstanding Young Lawyer in Shanghai." In 2023, he was awarded the title of "Fifth Oriental Distinguished Lawyer."

Highly Regarded Lawyer

Aurora Zhang

Ms. Zhang focuses her practice on venture capital financings, mergers & acquisitions, private equity investments, joint ventures, outbound and inbound investment, and general corporate matters. She has represented clients in various industries, including life sciences, healthcare, technology, manufacturing, etc.

In PE/VC area, Ms. Zhang has represented various of investment institutions in their domestic and/or overseas deals, her clients mainly include Sequoia Capital, Alibaba, CDH, PICC Capital, SummitView Capital, etc. Meanwhile, Ms. Zhang also represented several startups in their different rounds of financings, her clients include Momo Dim Sums, MetaX, etc.

In addition, Ms. Zhang has also advised several multinational enterprises and listed companies in their M&A deals or over their general corporate matters, her clients including Sinochem, Unifrax, BP, Porsche, etc.

The Lexpress Research Center focuses on the content of the submitted materials, confirmation through interviews with lawyers, feedback from relevant parties, and client evaluations. It pays particular attention to various dimensions, especially the professionalism displayed by lawyer teams in handling relatively complex cases, influential cases they have managed, the collaboration mechanisms within the team, and their efficiency in working together. Ultimately, it generates the "Brand Stars" honors for lawyers and "Brand Influence Law Firms" in five major fields for the 2024 annual recommendations: construction engineering, wealth management, industrial investment funds, biomedicine and healthcare, and capital markets.